HKiNEDA Survey Reveals INEDs’ Confidence in Hong Kong’s Dual-Listing Surge and Digital Frontier

HONG KONG, January 13, 2026 - (ACN Newswire via SeaPRwire.com) – The Hong Kong Independent Non-Executive Director Association (“HKiNEDA”) has released results from its 2025 Survey Questionnaire, polling 167 INEDs, advisors, and executives on the evolving landscape of corporate governance in dual listings, digital assets, Web3, and AI risks. Conducted…

Australia Developers Triumph at the 20th PropertyGuru Asia Property Awards Grand Final

AUSTRALIA’S FINEST REAL ESTATE EMERGES VICTORIOUS DURING CULMINATION OF THE 2025 PROPERTYGURU ASIA PROPERTY AWARDS SERIESBANGKOK, Jan 13, 2026 - (ACN Newswire via SeaPRwire.com) - The 20th edition of the PropertyGuru Asia Property Awards series has culminated in spectacular style at its Grand Final, distinguishing sublime achievements by development companies from…

Australia Developers Triumph at the 20th PropertyGuru Asia Property Awards Grand Final

AUSTRALIA’S FINEST REAL ESTATE EMERGES VICTORIOUS DURING CULMINATION OF THE 2025 PROPERTYGURU ASIA PROPERTY AWARDS SERIESBANGKOK, Jan 13, 2026 - (ACN Newswire via SeaPRwire.com) - The 20th edition of the PropertyGuru Asia Property Awards series has culminated in spectacular style at its Grand Final, distinguishing sublime achievements by development companies from…

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan

TOKYO and NEW YORK, NY., Jan 13, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO:…

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

TAIPEI, TW, Jan 12, 2026 - (ACN Newswire via SeaPRwire.com) - OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC.Under the terms of the agreement,…

Charlie’s Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape ProductsIKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products.The IKE Licensing Agreement provides CHUC with a first mover…